A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors.

Trial Profile

A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2014

At a glance

  • Drugs Iniparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top